Guía europea de prevención cardiovascular en la práctica clínica: Adaptación española del CEIPC 2008

Abstract

We present the Spanish adaptation from the CEIPC of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD by means of dealing with its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care medical doctors in promoting a healthy life style, based on increasing physical activity, change dietary habits, and non smoking. The therapeutic goal is to achieve a Blood Pressure <140/90 mmHg, but among patients with diabetes, chronic kidney disease, or definite CVD, the objective is <130/80 mmHg. Serum cholesterol should be <200 mg/dl and cLDL <130 mg/dl, although among patients with CVD or diabetes, the objective is <100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, with the objective guided by BMI -body mass index- and waist circumference. In diabetic type 2 patients, the objective is glycated haemoglobin <7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to put the recommendations into practice.

Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care

“…The CEIPC is an official alliance of 15 professional scientific societies supported by the Spanish Ministry of Health. Two national adaptations of the European guidelines for CVD prevention have been developed by CEIPC, the first in 2004 [2] and the second in 2008 [3]. These adaptations have introduced some changes with regard to treatment targets and implementation in order to reflect different social and medical circumstances.…”

Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study

“…Study subjects were over 18 years of age, with high CVR and confirmed hypercholesterolaemia, in other words, total cholesterol (TC) > 5.17 mmol/l or LDL-C > 3.36 mmol/l, or patients taking statins or other lipid-lowering drugs. High CVR was defined as a SCORE risk ≥ 5% or the presence of diabetes (type 2 or type 1 with microalbuminuria), or the presence of severe hyperlipidaemia (TC ≥ 8.28 mmol/l or LDL-C ≥ 6.21 mmol/l measured at the time of the visit), or severe hypertension (180/110 mmHg), following the recommendations in force in Spain (18).…”

“…Cholesterol control targets were established at each visit based on documented LDL-C levels and CEIPC 2008 guidelines (18). These targets were to reduce LDL-C < 2.59 mmol/l in patients with type 2 or type 1 diabetes or severe hyperlipidaemia and < 3.36 mmol/l in patients with none of the foregoing conditions.…”

Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol

“…The main difference between the SCORE risk chart and the Framingham model is that it estimates the risk for all atherothrombotic cardiovascular manifestations, including stroke, heart failure, peripheral arterial insufficiency or certain aneurysms, and not just CHD. The SCORE charts are currently the CVD charts recommended by the European Societies [44] and the Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention (CEIPC) [45]. The SCORE risk charts calibrated for Spain will be used [46].…”